Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts

• Status: Not yet recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the current work is to evaluate the efficacy and safety of intralesional combined Digoxin and furosemide versus intralesional 5-flurouracil in the treatment of plantar warts.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Digoxin; Fluorouracil; Furosemide

Criteria

Inclusion Criteria:

• Patients with multiple plantar warts (≥ 3) will be included.

Exclusion Criteria:

• Patients under 18 years old or patients over 65 years old.

• Pregnancy or breast feeding.

• Patients received vaccination or any other treatment of warts during the last month.

• Patients with a known sensitivity to any of the investigational product ingredients.

• Patients with history of asthma, allergic skin disorders or convulsions.

• Patients with signs of any systemic or local inflammation or infection.

• Patients with any evidence of immunosuppression including HIV.

• History of cardiac diseases, relevant abnormal K level or ECG abnormalities for patients who will receive the combined digoxin and furosemide.